NDAORALTABLET
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
CHILDREN'S ALLEGRA HIVES (fexofenadine hydrochloride) by Sanofi. Approved for hives, relieves itching due to hives (urticaria), an allergic skin reaction from occurring. First approved in 2000.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Children's Allegra Hives is an oral tablet formulation of fexofenadine hydrochloride, a non-sedating H1-receptor antagonist approved in 2000. It treats hives (urticaria) and relieves itching from allergic skin reactions. Fexofenadine works by blocking histamine receptors to prevent allergic responses.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting defensive strategy and potential team contraction ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHILDREN'S ALLEGRA HIVES at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.